A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Infigratinib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Sep 2016 This trial has been completed in Netherlands, according to European Clinical Trials Database.